Literature DB >> 27502600

The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositis.

Liguo Yin1, Yongpeng Ge2, Hanbo Yang2, Qinglin Peng2, Xin Lu2, Yamei Zhang2, Guochun Wang3,4.   

Abstract

The objectives of this study are to assess the levels of serum Interleukin-35 (IL-35) in patients with idiopathic inflammatory myopathies (IIMs) and to evaluate the association between IL-35 levels and IIM-related features. Serum IL-35 was detected in 76 patients with dermatomyositis (DM), 28 patients with polymyositis (PM), 98 disease controls (40 rheumatoid arthritis (RA), 34 systemic lupus erythematosus (SLE), 12 systemic sclerosis (SSc), and 12 sjogren syndrome (SS)), and 43 healthy controls by ELISA. Follow-up was conducted on 34 patients. Serum IL-35 was higher in myositis (PM/DM) patients than in healthy controls (median 76.6 pg/ml [interquartile range (IQR) 57.9-136.2] vs. 29.9 pg/ml (IQR 21.9-65.5), P < 0.001) and disease controls. Serum IL-35 in IIM patients negatively correlated with disease duration moderately (r = -0.35, P < 0.01). Patients with dysphagia had higher IL-35 than those without (median149.35 pg/ml (IQR 87.97-267.32) vs. 70.72 pg/ml (IQR 54.49-123.42), P = 0.001). Cross-sectional correlation analysis showed a weak positive correlation between serum IL-35 and CK (r = 0.293, P = 0.003), moderate positive correlation with erythrocyte sedimentation rate (ESR) (r = 0.304, P = 0.002), serum ferritin (SF) (r = 0.467, P = 0.001) and LDH levels (r = 0.401, P < 0.001). Additionally, serum IL-35 was higher in patients who were positive for anti-HMGCR (median 292.04 pg/ml (IQR 67.9-442.86) vs. 74.66 pg/ml (IQR 57.24-131.32), P = 0.038) and anti-SRP antibody (median 130.33 pg/ml (IQR 88.04-481.28) vs. 73.06 pg/ml (IQR 56.78-134.28), P = 0.009) than in negative patients, respectively. Follow-up study showed that changes in IL-35 levels after treatment correlated with changes in MYOACT scores moderately (r = 0.375, P = 0.029). These data indicate that increased serum IL-35 could act as a disease activity marker and as a risk factor for esophageal involvement in IIM. IL-35 may participate in the pathophysiological processes of IIM, but it still needs further study to confirm.

Entities:  

Keywords:  Biomarker; Cytokine; Dermatomyositis; Disease activity; Interleukin-35; Polymyositis

Mesh:

Substances:

Year:  2016        PMID: 27502600     DOI: 10.1007/s10067-016-3347-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  35 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

Review 2.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

3.  Antibody to signal recognition particle in polymyositis.

Authors:  I N Targoff; A E Johnson; F W Miller
Journal:  Arthritis Rheum       Date:  1990-09

4.  Quantification and molecular characterization of regulatory T cells in connective tissue diseases.

Authors:  Leontina Banica; Alina Besliu; Gina Pistol; Crina Stavaru; Ruxandra Ionescu; Ana-Maria Forsea; Cristina Tanaseanu; Sergiu Dumitrache; Dan Otelea; Isabela Tamsulea; Stefanita Tanaseanu; Cristina Chitonu; Simona Paraschiv; Monica Balteanu; Maria Stefanescu; Cristiana Matache
Journal:  Autoimmunity       Date:  2009-01       Impact factor: 2.815

5.  Interleukin-35 enhances Lyme arthritis in Borrelia-vaccinated and -infected mice.

Authors:  Joseph Kuo; Dean T Nardelli; Thomas F Warner; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2011-05-25

6.  Aberrant expression of regulatory cytokine IL-35 in patients with systemic lupus erythematosus.

Authors:  Z Cai; C K Wong; N W Kam; J Dong; D Jiao; M Chu; C W K Lam; L S Tam
Journal:  Lupus       Date:  2015-05-11       Impact factor: 2.911

7.  Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis.

Authors:  Mária Filková; Zdenka Vernerová; Hana Hulejová; Klára Prajzlerová; David Veigl; Karel Pavelka; Jiří Vencovský; Ladislav Šenolt
Journal:  Cytokine       Date:  2015-02-16       Impact factor: 3.861

8.  The effect of interleukin-35 on the integrity, ICAM-1 expression and apoptosis of human aortic smooth muscle cells.

Authors:  Wojciech Skowron; Katarzyna Zemanek; Katarzyna Wojdan; Paulina Gorzelak; Maciej Borowiec; Marlena Broncel; Maciej Chalubinski
Journal:  Pharmacol Rep       Date:  2014-11-06       Impact factor: 3.024

9.  IL-35-mediated induction of a potent regulatory T cell population.

Authors:  Lauren W Collison; Vandana Chaturvedi; Abigail L Henderson; Paul R Giacomin; Cliff Guy; Jaishree Bankoti; David Finkelstein; Karen Forbes; Creg J Workman; Scott A Brown; Jerold E Rehg; Michael L Jones; Hsiao-Tzu Ni; David Artis; Mary Jo Turk; Dario A A Vignali
Journal:  Nat Immunol       Date:  2010-10-17       Impact factor: 25.606

Review 10.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

View more
  7 in total

Review 1.  Update on outcome assessment in myositis.

Authors:  Lisa G Rider; Rohit Aggarwal; Pedro M Machado; Jean-Yves Hogrel; Ann M Reed; Lisa Christopher-Stine; Nicolino Ruperto
Journal:  Nat Rev Rheumatol       Date:  2018-04-12       Impact factor: 20.543

Review 2.  Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases.

Authors:  Cheng Ye; Hiroshi Yano; Creg J Workman; Dario A A Vignali
Journal:  J Interferon Cytokine Res       Date:  2021-11       Impact factor: 2.607

Review 3.  Pathogenesis and Function of Interleukin-35 in Rheumatoid Arthritis.

Authors:  Pan Lin Xin; Li Fan Jie; Qian Cheng; Du Yi Bin; Cheng Wen Dan
Journal:  Front Pharmacol       Date:  2021-05-13       Impact factor: 5.810

Review 4.  IL-35: a new immunomodulator in autoimmune rheumatic diseases.

Authors:  Lazaros I Sakkas; Athanasios Mavropoulos; Carlo Perricone; Dimitrios P Bogdanos
Journal:  Immunol Res       Date:  2018-06       Impact factor: 4.505

5.  Urine and serum interleukin 35 as potential biomarkers of lupus nephritis.

Authors:  Mary Atef Nassif
Journal:  Cent Eur J Immunol       Date:  2021-10-07       Impact factor: 2.085

Review 6.  Interleukin-35 in autoimmune dermatoses: Current concepts.

Authors:  Yuming Xie; Huilin Zhang; Junke Huang; Qing Zhang
Journal:  Open Med (Wars)       Date:  2022-03-21

7.  Soluble IL-2 Receptor in Dermatomyositis: Its Associations with Skin Ulcers and Disease Activity.

Authors:  Linrong He; Xiaoming Shu; Xia Liu; Yongpeng Ge; Sizhao Li; Xin Lu; Guochun Wang
Journal:  Mediators Inflamm       Date:  2020-07-28       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.